





















Takeda Oncology Pipeline

Beginning with patients' needs, we build our pipeline by identifying the most promising science and collaborate with leading teams around the globe to accelerate innovation. Our oncology R&D activities are focused on translating science into curative or transformative potential treatments by targeting tumor vulnerabilities and through novel strategies that leverage the power of innate immunity.

These therapies in development are investigational and have not been approved by any regulatory bodies for use in the investigational indications listed below.

| INVESTIGATIONAL THERAPY | PLATFORM | INVESTIGATIONAL INDICATION | PHASE | ADDITIONAL INFORMATION |
|----------------------------------|--------------------------|---|---|---|
| Cabozantinib* | Targeted therapy | <i>Metastatic castration-resistant prostate cancer (JP)</i> | Phase 3  | Tyrosine kinase inhibitor including MET/AXL/VEGFR Cabozantinib is being developed in Japan in collaboration with Exelixis. |
| Fruquintinib* | Targeted therapy | <i>Previously treated metastatic colorectal cancer (US, EU)</i> | Filed  | Oral VEGFR 1/2/3 tyrosine kinase inhibitor Takeda has development and commercialization rights for the treatment outside of mainland China, Hong Kong and Macau. |
| | | <i>Previously treated metastatic colorectal cancer (JP)</i> | Phase 3  | |
| Ixazomib* | Proteasome inhibitor | <i>Maint. newly diagnosed multiple myeloma post-stem cell transplant (US, EU)</i> | Phase 3  | Proteasome inhibitor |
| Mobocertinib* | Targeted therapy | <i>2L EGFR Exon20 insertion non-small cell lung cancer (JP)</i> | Phase 3  | Oral EGFR Exon20 tyrosine kinase inhibitor |
| | | <i>1L EGFR Exon20 insertion non-small cell lung cancer</i> | Phase 3  | |
| Ponatinib* | Targeted therapy | <i>FL Ph+ acute lymphocytic leukemia (US)</i> | Phase 3  | BCR-ABL inhibitor Takeda shares development rights with Incyte Corp. (Europe, Turkey and Israel) and Otsuka Pharm. (Asia Pacific territories). |
| | | <i>Pediatric Ph+ acute lymphoblastic leukemia</i> | Phase 1  | |
| Relugolix* (TAK-385) | Small molecule | <i>Prostate cancer (JP, Asian countries)</i> | Phase 3  | GnRH antagonist Relugolix is being developed in Japan and Asian countries in collaboration with Myovant Sciences, Inc. |
| Modakafusp Alfa (TAK-573) | Innate immunity enhancer | <i>Multiple myeloma</i> | Phase 1/2  | Innate immunity enhancer that functions through targeted next-generation interferon signaling Modakafusp alfa (TAK-573) was licensed from Teva Pharmaceuticals. |
| | | <i>Solid tumors</i> | Phase 1/2  | |
| Subasumstat (TAK-981) | Innate immunity enhancer | <i>Multiple cancers</i> | Phase 1/2  | SUMOylation inhibitor |

| INVESTIGATIONAL THERAPY | PLATFORM | INVESTIGATIONAL INDICATION | PHASE | ADDITIONAL INFORMATION |
|-------------------------|--------------------------|----------------------------|---|--|
| TAK-007 | Redirected immunity | <i>B-cell malignancies</i> | Phase 2  | CD19 CAR NK TAK-007 is being developed in collaboration with The University of Texas MD Anderson Cancer Center. |
| TAK-102 | Redirected immunity | <i>Solid tumors</i> | Phase 1  | GPC3 targeted CAR-T TAK-102 was licensed from Noile-Immune Biotech. |
| TAK-103 | Redirected immunity | <i>Solid tumors</i> | Phase 1  | Mesothelin targeted CAR-T TAK-103 was licensed from Noile-Immune Biotech. |
| TAK-186 | Redirected immunity | <i>Solid tumors</i> | Phase 1/2  | EGFR x CD3 targeting COBRA (COnditional Bispecific Redirected Activation) T cell engager immunotherapy |
| TAK-280 | Redirected immunity | <i>Solid tumors</i> | Phase 1/2  | B7-H3 x CD3 targeting COBRA (COnditional Bispecific Redirected Activation) T cell engager immunotherapy |
| TAK-500 | Innate immunity enhancer | <i>Solid tumors</i> | Phase 1  | CCR2-directed STING agonist |
| TAK-676 | Innate immunity enhancer | <i>Solid tumors</i> | Phase 1  | STING agonist |
| TAK-940 | Redirected immunity | <i>B-cell malignancies</i> | Phase 1  | CD19-1XX CAR-T TAK-940 is being developed in collaboration with Memorial Sloan Kettering Cancer Center. |

*Marketed products have received approval in one or more jurisdictions.

All programs have global development rights unless otherwise noted.

GL = global (USA, Europe, Japan, China) / EU = Europe / JP = Japan / CN = China / GEM = global emerging markets

   @TakedaOncology

Learn more at [TakedaOncology.com](https://www.takedaoncology.com)

©2023 Takeda Pharmaceuticals U.S.A., Inc.



ONCOLOGY